Alcohol use disorder treatment
Pro Research Analysisby 
Searched over 200M research papers
Alcohol Use Disorder Treatment: Current Challenges and Gaps
Alcohol use disorder (AUD) affects millions globally and is a leading cause of preventable death, yet treatment rates remain low. Only about one in six people with AUD receive any form of treatment, with even lower rates in low- and middle-income countries . Despite the availability of effective behavioral and pharmacological treatments, these options are greatly underutilized, creating a significant treatment gap 1238.
Evidence-Based Behavioral Treatments for AUD
Behavioral interventions are a cornerstone of AUD treatment. Cognitive behavioral therapy (CBT) has the most consistent evidence supporting its effectiveness in helping individuals reduce or stop alcohol use . Other behavioral approaches, such as motivational interviewing and contingency management, are also used, but none serve as a universal solution for all patients 28. Early engagement in treatment and reducing stigma are important strategies to improve treatment uptake .
Pharmacological Treatments: Approved and Emerging Options
Three medications are currently approved by the US Food and Drug Administration (FDA) for AUD: disulfiram, naltrexone (oral and injectable), and acamprosate 4579+1 MORE. Naltrexone, in particular, has been widely studied and shows moderate effectiveness in reducing relapse 2457. Disulfiram and acamprosate are also effective for some patients, but each medication has specific considerations, such as potential liver or kidney toxicity 710.
Beyond these, several other medications are being explored, including gabapentin, topiramate, baclofen, and varenicline, among others. Some of these are used off-label and show promise, but results are mixed and more research is needed 4569. The development of new medications and the repurposing of existing drugs remain high priorities to address the diverse needs of people with AUD 4569.
Special Populations and Tailored Approaches
Treatment for AUD must be tailored to special populations, such as pregnant women, individuals with liver or kidney disease, those experiencing homelessness, and adolescents. For example, psychosocial treatments are preferred for pregnant and nursing patients, while certain medications should be avoided in those with specific organ dysfunctions . Extended-release naltrexone may improve adherence in populations with unstable housing . Understanding and addressing the unique needs of these groups can improve treatment outcomes .
Barriers to Effective AUD Treatment
Several barriers hinder effective AUD treatment, including stigma, lack of awareness among healthcare providers and the public, and challenges in accurately measuring alcohol consumption and treatment response 168. There is also a need for better integration of screening, brief interventions, and referral to treatment in healthcare settings . Precision medicine—matching treatments to individual patient characteristics—remains an important but underdeveloped goal 256.
Future Directions: Precision Medicine and Novel Therapies
The heterogeneity of AUD means that no single treatment works for everyone. Ongoing research aims to identify new therapeutic targets and develop more personalized treatment strategies 1456. Advances in understanding the neurobiology and genetics of AUD may lead to more effective and individualized interventions in the future 1456+1 MORE.
Conclusion
Alcohol use disorder is a complex and widespread condition with significant health and social consequences. While effective behavioral and pharmacological treatments exist, they are underutilized, and treatment rates remain low. Expanding access, reducing stigma, developing new therapies, and tailoring treatment to individual and special population needs are critical steps to improving outcomes for those affected by AUD 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic